TY - JOUR
T1 - Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer
T2 - recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group
AU - Mulder, Renée L.
AU - Font-Gonzalez, Anna
AU - van Dulmen-den Broeder, Eline
AU - Quinn, Gwendolyn P.
AU - Ginsberg, Jill P.
AU - Loeffen, Erik A.H.
AU - Hudson, Melissa M.
AU - Burns, Karen C.
AU - van Santen, Hanneke M.
AU - Berger, Claire
AU - Diesch, Tamara
AU - Dirksen, Uta
AU - Giwercman, Aleksander
AU - Gracia, Clarisa
AU - Hunter, Sarah E.
AU - Kelvin, Joanne F.
AU - Klosky, James L.
AU - Laven, Joop S.E.
AU - Lockart, Barbara A.
AU - Neggers, Sebastian J.C.M.M.
AU - Peate, Michelle
AU - Phillips, Bob
AU - Reed, Damon R.
AU - Tinner, Eva Maria E.
AU - Byrne, Julianne
AU - Veening, Margreet
AU - van de Berg, Marleen
AU - Verhaak, Chris M.
AU - Anazodo, Antoinette
AU - Rodriguez-Wallberg, Kenny
AU - van den Heuvel-Eibrink, Marry M.
AU - Asogwa, Ogechukwu A.
AU - Brownsdon, Alexandra
AU - Wallace, W. Hamish
AU - Green, Daniel M.
AU - Skinner, Roderick
AU - Haupt, Riccardo
AU - Kenney, Lisa B.
AU - Levine, Jennifer
AU - van de Wetering, Marianne D.
AU - Tissing, Wim J.E.
AU - Paul, Norbert W.
AU - Kremer, Leontien C.M.
AU - Inthorn, Julia
AU - PanCareLIFE Consortium
PY - 2021
Y1 - 2021
N2 - Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.
AB - Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.
U2 - 10.1016/S1470-2045(20)30595-7
DO - 10.1016/S1470-2045(20)30595-7
M3 - Review article
C2 - 33539755
AN - SCOPUS:85100094498
SN - 1470-2045
VL - 22
SP - e68-e80
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 2
ER -